2. Academic Validation
  3. Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

Biarylsulfonamide CCR9 inhibitors for inflammatory bowel disease

  • Bioorg Med Chem Lett. 2015 Sep 1;25(17):3661-4. doi: 10.1016/j.bmcl.2015.06.046.
Jing Zhang 1,  Jan Romero 2,  Audrey Chan 2,  Jennifer Goss 2,  Sabrina Stucka 2,  Jason Cross 2,  Brian Chamberlain 2,  Mustafa Varoglu 2,  Haoqun Chandonnet 2,  Dominic Ryan 2,  Blaise Lippa 2
Affiliations

Affiliations

  • 1 Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States. Electronic address: [email protected].
  • 2 Cubist Pharmaceuticals, 65 Hayden Avenue, Lexington, MA 02421, United States.
PMID: 26117562 DOI: 10.1016/j.bmcl.2015.06.046
Abstract

Inflammatory bowel disease, including Crohn's disease and ulcerative colitis, affects millions of people worldwide. CCR9 has been shown to be a key Chemokine Receptor mediating the local inflammatory responses in the GI tract. The CCR9 inhibitor Vercirnon advanced to phase 3 clinical trials, but carries several liabilities which we sought to improve.

Keywords

CCR9; Crohn’s disease; IBD; Sulfonamide; Ulcerative colitis.

Figures
Products